title: Tocilizumab-induced psoriasiform rash in rheumatoid arthritis.
abstract: Tocilizumab (TCZ) is a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor and has been approved for the treatment of rheumatoid arthritis (RA) patients who have had an inadequate response to previous biological therapies. Psoriasiform skin lesions, especially palmoplantar pustulosis lesions, are well described following anti-tumour necrosis factor therapy. We describe a 79-year-old woman with rheumatoid factor-positive, anti-citrullinated protein antibody-positive erosive RA, who developed a psoriasiform palmoplantar pustulosis reaction following treatment with TCZ therapy (IL-6 receptor). The rash showed histological features compatible with psoriasis and disappeared following discontinuation of TCZ.
authors.affiliation: Rheumatology Division, Hospital General de Almansa, Almansa, Spain.
authors.forename: Natalia
authors.initials: N
authors.lastname: Palmou-Fontana
authors.forename: Juan Antonio
authors.initials: JA
authors.lastname: Sánchez Gaviño
authors.forename: Dennis
authors.initials: D
authors.lastname: McGonagle
authors.forename: Eva
authors.initials: E
authors.lastname: García-Martinez
authors.forename: Luis
authors.initials: L
authors.lastname: Iñiguez de Onzoño Martín
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D011565:Psoriasis / Q000139:chemically induced*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C502936:tocilizumab